R&D | January 23, 2026
Bayer and Vanderbilt launch five-year partnership to accelerate innovative therapies
The partnership initially will focus on cardiovascular and kidney diseases
The partnership initially will focus on cardiovascular and kidney diseases
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Subscribe To Our Newsletter & Stay Updated
